← Leaderboards
Jeffrey A Engelman
Massachusetts General Hospital
$5,049,484
Attributed
$7,663,211
Total exposure
4
Grants
2
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.3M · FY2006–15$2M$1.5M$1M$500K$0
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
Funding mix
By agency
NIH$7,663,211 · 4
By mechanism
R01$6,953,246 · 3
K08$709,965 · 1
Top collaborators
- Kwok Kin Wong7 shared
- Alice T Shaw4 shared
- Lecia V. Sequist1 shared
Most similar at Massachusetts General Hospital
Same institution · by research overlap
- Alice T Shaw$3,731,101
- Jessica Jiyeong Lin$1,690,059
- Joseph Vincent Bonventre$46,605,730
- Daniel A. Haber$29,412,047
- Arnab Chakravarti$9,324,533
Others in their field
Top investigators on “Malignant Neoplasm Of Lung”
- David Heimbrook · Leidos Biomedical Research, Inc.$349,639,893
- Richard K. Wilson · Washington University$202,666,376
- Walter John Curran · Thomas Jefferson University$94,674,902
- Jan C Buckner · Mayo Clinic Coll Of Medicine, Rochester$61,410,512
- Norman Wolmark · Nsabp Foundation, Inc.$54,610,124
- Leonard Freedman · Leidos Biomedical Research, Inc.$50,919,602
Research focus
Malignant Neoplasm Of LungResistanceMalignant NeoplasmsSignal PathwayPathway InteractionsResistance DevelopmentTumorEpidermal Growth Factor ReceptorEpidermal Growth Factor Receptor Tyrosine Kinase InhibitorInhibitor/AntagonistSignal TransductionMutantMutationSpecimenPhosphotransferasesIn VivoCellsApoptosisErlotinibResistance MechanismIn VitroGefitinibClinical TrialsTyrosine Kinase Inhibitor
Grant awards (22)
Therapeutic strategies for specific subsets of KRAS mutant lung cancers$512,243
R01 · FY2015 · CA
Impact of heterogeneity on response to EGFR T790M inhibitors$406,220
R01 · FY2015 · CA · contact PI
Identification of Resistance Mechanisms to Anaplastic Lymphoma Kinase Inhibitors$351,837
R01 · FY2015 · CA
Therapeutic strategies for specific subsets of KRAS mutant lung cancers$496,876
R01 · FY2014 · CA
Identification of Resistance Mechanisms to Anaplastic Lymphoma Kinase Inhibitors$341,282
R01 · FY2014 · CA
Therapeutic strategies for specific subsets of KRAS mutant lung cancers$530,993
R01 · FY2013 · CA
Identification of Resistance Mechanisms to Anaplastic Lymphoma Kinase Inhibitors$330,727
R01 · FY2013 · CA
The Activation of ERBB3 Signaling as a Resistance Mechanism to Targeted Therapies$320,957
R01 · FY2013 · CA · contact PI
Inhibition of P13k and MEK Pathways in the Treatment of Lung Cancer$496,412
R01 · FY2012 · CA
Identification of Resistance Mechanisms to Anaplastic Lymphoma Kinase Inhibitors$353,463
R01 · FY2012 · CA
The Activation of ERBB3 Signaling as a Resistance Mechanism to Targeted Therapies$341,443
R01 · FY2012 · CA · contact PI
Inhibition of P13k and MEK Pathways in the Treatment of Lung Cancer$496,752
R01 · FY2011 · CA
The Activation of ERBB3 Signaling as a Resistance Mechanism to Targeted Therapies$341,443
R01 · FY2011 · CA · contact PI
Inhibition of P13k and MEK Pathways in the Treatment of Lung Cancer$476,188
R01 · FY2010 · CA
The Activation of ERBB3 Signaling as a Resistance Mechanism to Targeted Therapies$352,003
R01 · FY2010 · CA · contact PI
Molecular mechanisms of PI3K activation in non-small cell lung cancer$143,775
K08 · FY2010 · CA · contact PI
Inhibition of P13k and MEK Pathways in the Treatment of Lung Cancer$434,462
R01 · FY2009 · CA
The Activation of ERBB3 Signaling as a Resistance Mechanism to Targeted Therapies$369,945
R01 · FY2009 · CA · contact PI
Molecular mechanisms of PI3K activation in non-small cell lung cancer$142,965
K08 · FY2009 · CA · contact PI
Molecular mechanisms of PI3K activation in non-small cell lung cancer$142,155
K08 · FY2008 · CA · contact PI
Molecular mechanisms of PI3K activation in non-small cell lung cancer$141,345
K08 · FY2007 · CA · contact PI
Molecular mechanisms of PI3K activation in non-small cell lung cancer$139,725
K08 · FY2006 · CA · contact PI